397 related articles for article (PubMed ID: 2449118)
21. Surface expression of tumor-associated antigens in primary cultured human colonic epithelial cells from carcinomas, benign tumors, and normal tissues.
Friedman E; Thor A; Hand PH; Schlom J
Cancer Res; 1985 Nov; 45(11 Pt 2):5648-55. PubMed ID: 2413994
[TBL] [Abstract][Full Text] [Related]
22. Mouse monoclonal antibody to embryonic antigen: development, cross-reactivity with rodent and human tumors, and preliminary polypeptide characterization.
Payne WJ; Coggin JH
J Natl Cancer Inst; 1985 Sep; 75(3):527-44. PubMed ID: 2411994
[TBL] [Abstract][Full Text] [Related]
23. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
24. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins.
Partin AW; Briggman JV; Subong EN; Szaro R; Oreper A; Wiesbrock S; Meyer J; Coffey DS; Epstein JI
Urology; 1997 Nov; 50(5):800-8. PubMed ID: 9372899
[TBL] [Abstract][Full Text] [Related]
25. Distribution of lung adenocarcinoma-associated antigens in human tissues and sera defined by monoclonal antibodies KM-52 and KM-93.
Shitara K; Hanai N; Yoshida H
Cancer Res; 1987 Mar; 47(5):1267-72. PubMed ID: 3545444
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibody to human carcinoma-associated protein complex: quantitation in normal and tumor tissue.
Falcioni R; Sacchi A; Resau J; Kennel SJ
Cancer Res; 1988 Feb; 48(4):816-21. PubMed ID: 2448027
[TBL] [Abstract][Full Text] [Related]
27. Human tetranectin: methodological and clinical studies.
Høgdall CK
APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
[TBL] [Abstract][Full Text] [Related]
28. [Experience with prostate-specific antigen in patients with prostatic cancer].
Romics I; Bach D
Orv Hetil; 1989 Dec; 130(52):2797-800. PubMed ID: 2481833
[TBL] [Abstract][Full Text] [Related]
29. Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients.
Holmes EH; Greene TG; Tino WT; Boynton AL; Aldape HC; Misrock SL; Murphy GP
Prostate Suppl; 1996; 7():25-9. PubMed ID: 8950359
[TBL] [Abstract][Full Text] [Related]
30. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
Morote Robles J; de Torres Mateos JA
Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
[TBL] [Abstract][Full Text] [Related]
31. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
[TBL] [Abstract][Full Text] [Related]
32. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
33. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates.
Li Y; Abbas Rizvi SM; Blair nee Brown JM; Cozzi PJ; Qu CF; Ow KT; Tam PN; Perkins AC; Russell PJ; Allen BJ
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):896-908. PubMed ID: 15465208
[TBL] [Abstract][Full Text] [Related]
34. Cross-reactivity of murine anti-human high molecular weight-melanoma associated antigen monoclonal antibodies with guinea pig melanoma cells.
Liao SK; Smith JW; Kwong PC; Natali PG; Kusama M; Hamby CV; Ferrone S
Cancer Res; 1987 Sep; 47(18):4835-41. PubMed ID: 3476198
[TBL] [Abstract][Full Text] [Related]
35. Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen.
Cavacini LA; Duval M; Eder JP; Posner MR
Clin Cancer Res; 2002 Feb; 8(2):368-73. PubMed ID: 11839651
[TBL] [Abstract][Full Text] [Related]
36. Immunohistological analysis of thymic tumors with PE-35 monoclonal antibody reactive with medullary thymic epithelium.
Takahashi T; Ueda R; Nishida K; Namikawa R; Fukami H; Matsuyama M; Masaoka A; Imaizumi M; Takahashi T
Cancer Res; 1988 Apr; 48(7):1896-903. PubMed ID: 2450640
[TBL] [Abstract][Full Text] [Related]
37. In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate.
Bocker T; Bittinger A; Wieland W; Buettner R; Fauser G; Hofstaedter F; Rüschoff J
Mod Pathol; 1995 Apr; 8(3):226-31. PubMed ID: 7542384
[TBL] [Abstract][Full Text] [Related]
38. [Prostate-specific antigen. A new marker of prostatic pathology].
Boccon-Gibod L; Géraud M; Dugué MA
Ann Urol (Paris); 1988; 22(3):206-10. PubMed ID: 2456714
[TBL] [Abstract][Full Text] [Related]
39. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate.
Barak M; Mecz Y; Lurie A; Gruener N
J Lab Clin Med; 1989 May; 113(5):598-603. PubMed ID: 2469756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
